|909cQ9UT0Tc G!&!|8KKKJ t9 y x^B33 2Z=mx8=m? !h/``X #^%D+DSRFhF^w _66#[#6w_aC# 19J1j1#;P ~i $uW2xWcUA:%+LW })LBinsi =e!s{V /gW:F. 0+bMp3MF)b)p K*a pTyHGhTp o# @1T1@1X6 7mm}h6AUMh K+DKtK_K?+ \/ 6X{? P3y yfQW dyefD! 4+o3(~(. =b v[3:gplp:Og B^AQ-0B3 yV43$13@X4X$ aTD PBZgi y5 qL#E X?rX Xq#qztvcvt\ \bv Cd\q }_4} ryAN m`Tawa`@am`@`nG SMF 7Scvr3\7 ~YjY~y Sa q`qh& [j\ *jtm=a#a dk&yBd 10~1@1R1+0 ~T K-D#22c ,5e}1}04 gJc\*U0 nXiun%Xi99 b!::,.
Zanubrutinib MoA slide kit
Zanubrutinib (BGB-3111) is a small molecule, orally administered, irreversible inhibitor of Bruton’s Tyrosine Kinase (BTK). Here we provide a summary of the BTK signaling pathway, outline some challenges to BTK inhibition and describe how zanubrutinib was designed. We also explain the kinase selectivity and pharmacokinetics of zanubrutinib and provide important data describing zanubrutinib’s BTK occupancy in PBMCs and lymph nodes.
Slide-Kit
20 Mar 2024
